Bausch Health Companies Inc.’s $1.5 Billion incremental term loan facility

Cahill represented the lead arrangers in connection with $1,500,000,000 incremental term loan facility for Bausch Health Companies Inc. Cahill also represented the dealer managers in connection with a tender offer to purchase any and all of Bausch Health Companies Inc.’s outstanding 7.500% Senior Notes due 2021.

Barclays Bank acted as Administrative Agent on the transaction.

Bausch Health Companies Inc., formerly Valeant Pharmaceuticals International, Inc., is a multinational specialty pharmaceutical company. Proceeds from the loan will be used for general corporate purposes and to refinance existing indebtedness.

Cahill advised with a team including Timothy B. Howell (Picture), Noah B. Newitz, Josiah M. Slotnick, Lisa Collier, Alexandria Fernandez, Yekaterina Fomitcheva, Mark Loftus, Philip Merenda, Emma K. O’Hara, Ani Ravi and Bryan R. Seelig

Involved fees earner: Lisa Collier – Cahill Gordon & Reindel; Alexandria Fernandez – Cahill Gordon & Reindel; Yekaterina Fomitcheva – Cahill Gordon & Reindel; Timothy Howell – Cahill Gordon & Reindel; Mark Loftus – Cahill Gordon & Reindel; Philip Merenda – Cahill Gordon & Reindel; Noah Newitz – Cahill Gordon & Reindel; Emma O’Hara – Cahill Gordon & Reindel; Ani Ravi – Cahill Gordon & Reindel; Bryan Seelig – Cahill Gordon & Reindel; Josiah Slotnick – Cahill Gordon & Reindel;

Law Firms: Cahill Gordon & Reindel;

Clients: Barclays Bank;

Author: Ambrogio Visconti